The immune response is modulated by genetic adjuvants using plasmid vectors expressing cytokines. Skeletal muscle can express a foreign gene intramuscularly administered via a needle injection, and the potential of muscle as a target tissue for somatic gene therapy in treating cancer has been explored. In the present study, we investigated the efficacy of particle-mediated intramuscular transfection modified with a local anesthetic agent, bupivacaine, on luciferase and green fluorescent protein. The results indicate that these proteins are more efficiently expressed and persist longer in muscle modified in this way compared with the needleinjection method. Using an established rat sarcoma model, particle-mediated intramuscular gene-gun therapy with a combination of IL-12 and IL-18 cDNA was conducted. Growth of the distant sarcoma was significantly inhibited by particle-mediated intramuscular combination gene therapy, and the survival rate was also improved. Furthermore, the combination gene-gun therapy maintained significant levels of interferon-g and induced a high activity of tumor-specific cytotoxic T lymphocytes. These results suggest that the sustained local delivery of IL-12 and IL-18 cDNA using intramuscular gene-gun therapy modified with bupivacaine can induce long-term antitumor immunity, and can provide the great advantage of inhibiting the disseminated tumor.
I mmunization with DNA expression plasmids has great potential to induce humoral and cellular immune responses that protect against a number of infectious diseases as well as cancer. 1 The immune response also can be modulated by genetic adjuvants using vectors expressing biologically active cytokines. 2 DNA-based therapy and immunization have primarily been performed using either intradermal or intramuscular routes. Skeletal muscle can principally express a foreign gene intramuscularly administered by needle syringe injection, 3 making it a potential target tissue for somatic gene therapy of muscle and nonmuscle diseases. 4 However, expression levels of the transfected reporter gene remain low, and emerging data suggest that regenerating muscle fibers may more efficiently express the transgene than normal muscle fibers without any modification. 5, 6 Long-term persistence of foreign gene expression can be advantageous in providing a continuous supply of cytokines against cancer. 7 The gene gun is a useful device for particle-mediated gene transfer, and can deliver cytokine genes into the in vivo microenvironment of a living animal without any type of viral vector. [8] [9] [10] Since gene guns also have the advantages of being fast, simple, and versatile, 8, 11 they could easily be used to deliver foreign genes into muscle as well as into skin. Gene-gun-mediated in vivo transfection of cytokine genes has recently resulted in the regression of tumors in rodent cancer animal models. [12] [13] [14] This technique also allows multiple genes to deliver to the target tissue, and is most suitable for assessing the combination therapy of cytokine genes.
Recent advances in cancer therapy have focused on cytokine-mediated antitumor effects. [15] [16] [17] Anticancer cytokines then allow for the development of an immunotherapy. Among the many cytokines evaluated as antitumor agents, interleukin (IL)-12 has been shown to have a highly potent immune-mediated antitumor response in many tumor models.
12,18-21 IL-12 functions as a heterodimeric protein (p35 and p40) that strongly enhances the Th1-type immune response. 22, 23 The antitumor effects of IL-12 are mediated by activation of cytotoxic T lymphocytes (CTL) and natural killer (NK) cells, [23] [24] [25] [26] and by production of interferon (IFN)-g from T cells and NK cells. 20, 27 However, IL-18, originally termed IFN-g-inducing factor (IGIF), is also a costimulatory factor in the activation of Th1 cells. IL-18 can induce IFN-g production in both T cells and NK cells. [28] [29] [30] In addition, IL-18 also induces T cells to produce granulocyte-macrophage colony stimulating factor, augments IL-2 production by antigen-or anti-CD3-stimulated murine Th1 clones, induces IL-2-dependent proliferation of these stimulated cells, and enhances the cytolytic activity of T cells and NK cells. [31] [32] [33] [34] [35] IL-18 is synthesized as a biologically inactive precursor protein (pro-IL-18). To generate the active form of IL-18, pro-IL-18 must be processed by the intracellular cysteine protease, the IL-1b converting enzyme (ICE), at the Asp-X cleavage site. 36, 37 The processing of pro-IL-18 by ICE facilitates secretion of the mature and active form of the IL-18 protein. 37 Based on the findings that both IL-12 and IL-18 can strongly enhance the cytotoxic activities of CTL and NK cells, and can synergistically produce IFN-g, 32 ,38 a combination of IL-12 and IL-18 has been demonstrated to produce superior antitumor activity over either IL-12 or IL-18 treatment alone. [39] [40] [41] However, the systemic administration of recombinant IL-12 and IL-18 proteins, although superior in effectiveness in inducing tumor inhibition, has resulted in the death of animals because of severe toxicity. 42, 43 Therefore, the topical transfer of cytokine genes may circumvent some of the toxicity of systemic IL-12 delivery, and may provide adequate cytokine levels for immune-cell activation.
We have shown in the present study that particlemediated gene transfer can more efficiently introduce foreign plasmid DNA into rat regenerating muscle than authentic intramuscular needle injection. Furthermore, gene-gun-mediated combination therapy with IL-12 and IL-18 cDNA into skeletal muscle was found to inhibit synergistically the rapid growth of distant Yoshida sarcoma in syngenic-transplanted rats and to improve the survival rate. The persistent gene expression of antitumor cytokines in skeletal muscle using a gene gun may provide a great advantage in inhibiting disseminated malignant tumors.
Materials and methods

Rats, cells, and plasmids
Male 6-week-old Lewis and Donryu rats were purchased from Charles River Japan, Inc. (Tsukuba, Japan), and were maintained in the Experimental Animal Center of Jichi Medical School.
The Yoshida sarcoma cells were kindly donated by the Kyowa Hakko Co. Ltd (Tokyo, Japan), and were maintained in the ascites of several Donryu rats. Cells in exponential growth were harvested by trypsinization and washed twice in phosphate-buffered saline (PBS). Cell viability was determined by trypan blue dye exclusion. The 293T cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. The cultures were kept in a 5% CO 2 and 95% air humidified atmosphere at 371C.
The mouse IL-18 expression plasmid, designated pcDNA-mpro-IL-18-mICE, was constructed as follows. Both the mouse pro-IL-18 and ICE cDNAs (kindly donated by Dr K Oshikawa, Jichi Medical School, Tochigi, Japan) 41 were modified to clone into the pcDNA3.1 expression vector (Invitrogen, San Diego, CA), driven under a CMV promoter. The EcoRI fragment containing the entire coding sequence of the mouse pro-IL-18 from pNGVL-mIL-18 was inserted into the EcoRI site of pcDNA3.1 to generate pcDNA-mpro-IL-18, and the XhoI-BamHI fragment containing the full length of ICE from pCR3.1-ICE was inserted into the XhoI-BamHI site of pcDNA3.1 to generate pcDNAmICE. The MunI-NaeI fragment from pcDNA-mpro-IL-18 was ligated into the MunI-NruI site in pcDNA-mICE to generate pcDNA-mpro-IL-18-mICE. The mouse IL-12 expression plasmid, pCAGGS-IL-12, 10 was kindly provided by Dr S Wolf of the Genetic Institute (Cambridge, MA) and contained both IL-12 p35 and p40 cDNA driven under a chicken b-actin gene promoter. The Renilla reniformis luciferase expression plasmid, pRL-TK, was obtained from Promega (Madison, WI), and its gene was driven under a herpes simplex virus thymidine kinase (HSV-tk) promoter. The expression construct for an enhanced type of mutant in the green fluorescent protein (GFP) gene, phGFP-105-C1, 44 driven under a cytomegalovirus (CMV) promoter, was kindly donated by Dr T Osumi, Himeji Institute of Technology (Hyogo, Japan). Large-scale preparation of plasmid DNA was performed by the alkaline lysis method, and closed circular plasmid DNA was purified by equilibrium centrifugation in CsClethidium-bromide gradients.
Treatment with bupivacaine in rat skeletal muscle A lateral skin incision (approximately 4 cm) was made in the thighs of the rat, and the hamstring muscles were separated with blunt-ended forceps at 1-cm lengths along the long axis of the muscle fibers. Next, 0.5 ml of 0.5% bupivacaine was injected into the muscle using a 27-gauge needle. After intramuscular injection, the incision was closed with a suture. The rats were maintained in a pathogen-free room under controlled environmental conditions. The rats were anesthetized with ketamine and xylazine for all procedures.
Particle-mediated gene delivery
The Helios TM gene-gun system (Bio-Rad Laboratories, Tokyo) was used according to the instruction manual of the manufacturer. Plasmid DNA was precipitated onto 1.6-mm gold particles as described previously. 9, 45 The suspension of plasmid DNA-coated gold particles was introduced into a Tefzel s tube (Bio-Rad) placed on a flow of nitrogen (0.4 ml/minutes) for 15 minutes. The tube was then cut into 1.2-cm-length cartridges and stored in a container with silica gel at À201C. One milligram of gold particles contained 2.0 mg of plasmid DNA, resulting in delivery of 1.0 mg of DNA per shot.
After intramuscular injection of bupivacaine, the rat skeletal muscle was exposed by reopening the suture, and was then bombarded by the gene gun at 350 psi (1 psi ¼ 6890 Pa) with a single shot. For comparison, an intramuscular injection consisting of 0.5 ml of PBS containing 1.0 mg of plasmid DNA was performed 4 days after bupivacaine treatment. The skin was sutured after transfection, and the rats were kept under the same conditions as stated above until further analysis.
Luciferase assay
The expression plasmids of phGFP-105-C1 and pRL-TK were mixed to a ratio of 1:9 and were then precipitated onto gold particles as described above. The expression area of the introduced GFP gene was easily visualized under an excitation light of 489 nm and punched out with a 6-mm diameter at the indicated period after transfection. The luciferase activity was measured using a Luciferase Reporter assay system (Promega, Madison, WI). Each assay was independently repeated several times, and the average value was indicated. The activity was dependent on the incubation time and the protein concentration used for the assay.
In vitro transfection and cytokine bioassay
The 293T cells (1 Â 10 5 cells) were seeded into a 60-mm culture dish. Expression plasmid (5 mg) was transfected by the calcium phosphate procedure. 46 Culture supernatants were harvested at 36 hours post-transfection. The supernatants were also evaluated by enzyme-linked immunoassay analysis (ELISA) to detect IL-18 and IL-12 (IL-12, R&D systems, Minneapolis, MN; IL-18, MBL, Nagoya, Japan). The relative biological activity of IL-12 and IL-18 was determined based on the ability of the cell supernatants to augment IFN-g production in vitro. 29 Briefly, rat splenocytes (2 Â 10 6 cells) were cocultured with concanavalin (Con A) (5 mg/ml) in 24-well plates for 24 h. Supernatants from the transfected 293T cells were added to the cell suspension of Con A-primed splenocytes (1 Â 10 6 cells) for 24 hours. The supernatants were collected and assayed by ELISA to detect IFN-g production (R&D systems).
ELISA of IL-12, IL-18, and IFN-g
The rats were bled from the retro-orbital plexus. The blood was centrifuged at 4000 rpm for 10 minutes, and the serum was collected using serum separators. It was used for ELISA of IL-12, IL-18, and IFN-g, following the manufacturer's instructions. The color changes were read by a precision microplate reader (Bio-Rad Laboratories, Tokyo).
Cell-mediated killing assay
The Cytotoxicity Detection Kit (Roche, Mannheim, Germany) was used for the CTL assay. Briefly, Yoshida sarcoma cells irradiated with 80 Gy were used as stimulator cells. Spleen cells from the treated rats were stimulated with irradiated sarcoma cells at a 20:1 ratio for 5 days. Stimulated effector cells were incubated with the target cells at various ratios in 96-well round-bottomed plates for 5 hours at 371C. The supernatant was then assayed according to the instruction manual (Roche). The percentage cytotoxicity was calculated as follows: cytotoxicity (%) ¼ (experimental valueÀlow control) Â 100/ (high controlÀlow control). High control was obtained by incubating the target cells with 0.5% Triton X-100, while low control was obtained by incubating the target cell alone. The percentage cytotoxicity was calculated as the average of triplicate assays.
Rat sarcoma model and in vivo treatment protocol
For the sarcoma model, the rats were shaved in the abdominal area and injected subcutaneously with 1 Â 10 5 Yoshida sarcoma cells. There were four groups of genegun-treated rats: those treated with IL-12, IL-18, or both, and those with control GFP expression vectors. Tumor growth was monitored two or three times per week by measurement of two perpendicular tumor diameters. Tumor volume was then evaluated using the following equation: tumor volume ¼ (length in mm) Â (width in mm) 2 /2.
10, 45 The above provides an approximation of the volume of an ellipsoid, and can be considered a valid estimate of tumor size assuming unit density.
In vivo depletion of CD4 + , CD8 + T cells, and NK cells
Anti-rat CD4 (clone OX35, IgG2a) and anti-rat CD8 monoclonal antibodies (clone OX8, IgG1) were purified from the supernatant of the hybridoma cells, which were kindly provided by Dr Y Matsumoto, Tokyo Metropolitan Institute for Neuroscience (Tokyo, Japan). Briefly, the hybridomas were cultured in GIT medium (Wako, Osaka, Japan), and the antibodies were then purified via passage over an affinity-gel protein G column (Amersham Biosciences, Osaka, Japan). To deplete host CD4 + or CD8 + T cells subsets in vivo, the rats were intraperitoneally injected with 10 mg/kg of anti-CD4, anti-CD8, or anti-rat IgG control antibody (Sigma Chemicals, Tokyo, Japan) on days 0, 1, 2, 3, 6, and 8 of tumor challenge. To deplete NK cells, 250 mg of antiasialo GM1 antibody (Wako, Osaka, Japan) was intraperitoneally injected. The tumor-bearing rats underwent combination gene-gun therapy with IL-12 plus IL-18 on day 4 of tumor challenge. Tumor size was monitored two or three times per week.
Statistical analysis
Data are presented as mean7standard deviation (SD). Statistical differences between the two groups were evaluated using the unpaired Student's t-test. The survival rates were analyzed by means of the Kaplan-Meier 
Results
Effective gene-gun transfection into rat skeletal muscle pretreated with bupivacaine Gene-gun-based transfection is one of the most efficient in vivo methods of local gene delivery employing no viral vectors. Skeletal muscle as well as skin is the most applicable tissue for the local gene delivery, although the expression of foreign genes in muscle is limited even using gene-gun-based technology. 8 Intramuscular administration of local anesthetic agents, however, increases cell-membrane permeability, 47 which may enhance the expression of foreign genes in muscle. We tested whether local anesthetic agents can enhance foreign gene expression in skeletal muscle. The muscles of Lewis rats were treated with various local anesthetic agents 4 days before gene-gun transfection, as shown in Figure 1a . The luciferase reporter gene driven by an HSV-tk promoter was then transfected into the rat skeletal muscle using the gene gun. Bupivacaine pretreatment activated the luciferase reporter gene the most among the examined local anesthetics at 1 day post-transfection. As shown in Figure 1b , the optimal interval after bupivacaine injection for luciferase gene expression was determined. The expression of the luciferase gene was enhanced the most at 4 days postbupivacaine treatment.
We also evaluated how long the transfected gene could be expressed in the rat skeletal muscle that had been pretreated with bupivacaine using the gene gun compared with the needle-injection method. As shown in Figure 1c , the luciferase activity at 1 day post-transfection in the muscle treated with bupivacaine before gene-gun transfection was 21-fold higher than that in the control treatment, and seven-fold higher than that in response to intramuscular needle injection combined with bupivacaine treatment. The high expression of luciferase gene in the bupivacaine-treated muscle was maintained for at least 28 days postgene-gun transfection. The luciferase activity in the group of bupivacaine plus gene gun was five-fold higher than in the group of bupivacaine plus direct injection of the naked plasmid at 28 day post-transfection. These results indicate that intramuscular particlemediated gene transfer combined with bupivacaine treatment can efficiently introduce long-lasting gene expression into skeletal muscle.
Enhanced foreign gene expression in muscle with bupivacaine pretreatment
We tested whether GFP gene expression can be enhanced in muscle modified with bupivacaine using the gene gun. GFP expression was significantly enhanced in the muscle fibers pretreated with bupivacaine, which was easily detected under a 489-nm excitation light at 1 day posttransfection (Fig 2a) . This expression is in sharp contrast to that in the muscles not pretreated with bupivacaine (Fig 2b) or those that underwent authentic intramuscular needle injection of the reporter plasmid (Fig 2c) . GFP expression was visible in numerous muscle fibers at day 28 (Fig 2d) . Notably, GFP expression was observed for at least 6 months, although the number of GFP-expressing fibers gradually decreased throughout that period (data not shown). On the other hand, GFP expression in the group receiving direct intramuscular needle injections was extremely low, having completely disappeared by day 7 after the needle injection (Fig 2c) .
Combination of IL-12 and IL-18 strongly introduces IFN-g production from splenocytes in vitro
The coexpression of pro-IL-18 with ICE, but not pro-IL-18 alone, results in the secretion of biologically active IL-18 protein. 36 The cleavage of pro-IL-18 (24 kDa) by ICE results in the secretion of the biologically active form of IL-18 (18 kDa) from cells. 37 In the present study, the pro-IL-18 and ICE cDNA were used from a physiological viewpoint, instead of focusing on the transfection of the genetically engineered mature form of IL-18 cDNA. To confirm that the expression construct of pcDNA-mpro-IL-18/mICE can generate the mature form of IL-18 from cells, 293T cells were transfected with pcDNA-mpro-IL-18/mICE, and expression levels were then evaluated by ELISA. High levels of IL-18 were detected in the supernatant of transfectants with pcDNA-mpro-IL-18/ mICE (Fig 3a, lane 5) , and both pcDNA-mpro-IL-18 and pcDNA-mICE (lane 4), but not with pcDNA-mICE (lane 2), or pcDNA-mpro-IL-18 alone (lane 3). These results indicate that pcDNA-mpro-IL-18/mICE should be able to secrete the biologically active mature form of IL-18 from the transfected cells.
We then evaluated whether the addition of the mIL-12 expression plasmid could enhance IFN-g production in vitro. The higher level of IL-12 was easily detected in the supernatant of pCAGGS-IL-12 transfectant (Fig 3b,  lanes 6-10) . As shown in Figure 3c , the combination of pCAGGS-IL-12 and pcDNA-mpro-IL-18/mICE (lane 10), or both pcDNA-mpro-IL-18 and pcDNA-mICE (lane 9), resulted in the highest level of IFN-g secretion from Con A-primed rat splenocytes among all transfectants. The IFN-g production of each culture supernatant was inhibited by preincubation with anti-mouse IL-12 or IL-18 neutralizing antibody or both (data not shown). Therefore, the IFN-g production in vitro from Con Aprimed rat splenocytes depended on IL-12 and/or IL-18, and IL-12 synergistically introduced IFN-g production in combination with the mature IL-18 produced from ICEcleaved pro-IL-18, but not with immature pro-IL-18 alone.
Combination gene-gun therapy in rat skeletal muscle using IL-12 and IL-18 cDNA inhibits the tumor growth of Yoshida sarcoma in vivo Gene therapy with IL-12 has been shown to elicit a potent systemic antitumor effect in a variety of tumors. 12 The
Long-lasting gene expression by gene gun T Ajiki et al Long-lasting gene expression by gene gun T Ajiki et al synergistic IFN-g induction via a combination of IL-12 and mature IL-18 treatment led us to examine whether the combination could also result in marked suppression of established tumors at distant sites. We implanted Yoshida sarcoma cells (1 Â 10 5 cells) into the upper abdominal skin of syngeneic male Donryu rats whose muscles had been treated with 0.5 ml of 0.5% bupivacaine, resulting in the successful establishment of a sarcoma model at 4 days postimplantation. There was no significant difference in tumor size between experimental groups on that day. We then examined the systemic effects of the intramuscular gene-gun treatment modified with bupivacaine on the implanted, highly aggressive sarcoma as a distant metastatic model. The sarcoma in the rat was treated only once, using the gene gun, on day 4 after the tumor implantation. As shown in Figure 4a , the gene-gun therapy with both pCAGGS-IL-12 and pcDNA-mpro-IL-18/mICE resulted in the most significant suppression of the implanted sarcoma by the 10th day after tumor implantation, compared to that with the control GFP (Po.001) or IL-18 expression vector alone (Po.001). The therapy with IL-12 cDNA alone was somewhat effective but did not achieve the same results as the combination of pCAGGS-IL-12 and pcDNA-mpro-IL-18/mICE (Po.05). The antitumor effect of this combination also contributed to an improvement in the survival rate, and the lifespan of the rats in the combination gene-gun therapy of IL-12 and IL-18 was significantly increased (Fig 4b) . No obvious side effects or body weight loss were observed in the course of the gene-gun treatment. The control treatment with the GFP expression plasmid led to the fatal development of large tumors in the rats by day 11 post-tumor implantation. Furthermore, the combination gene therapy using intramuscular needle injection with bupivacaine pretreatment did not produce the same results as the combination therapy using the gene gun (Po.001) (Fig 4c) . The rats receiving the combination gene therapy using the gene gun with bupivacaine pretreatment had a significantly better survival rate (Fig 4d) . In contrast, the rats with needle injection therapy had a poor survival rate, and all of the control rats treated with GFP plasmid using direct needle injection were dead from the tumor around day 11. 
Long-lasting gene expression by gene gun T Ajiki et al
Notably, complete tumor regression was also observed on day 20 in 60% of the rats in the IL-12 plus IL-18 treatment group, and in 40% in the group with IL-12 cDNA alone. Those rats with complete regression after the gene-gun bombardment of IL-12 and IL-18 cDNA were again implanted with 1 Â 10 5 Yoshida sarcoma cells on day 30. However, the result was that all of the rats rejected the sarcomas and remained free of tumors for an additional 2 months (data not shown).
Combinatorial intramuscular gene-gun therapy of IL-12 and IL-18 induces cell-mediated killing activity against Yoshida sarcoma
To determine whether specific cytotoxic T cell (CTL) against Yoshida sarcoma could be induced after IL-12 plus IL-18 gene therapy using the gene gun, cell-mediated killing activity of the spleen cells from the rats receiving gene therapy against sarcoma cells was measured at 7 Figure 5 , CTL activity in the IL-12 plus IL-18 combination therapy using the gene gun following pretreatment of muscle with bupivacaine was significantly higher than that of the gene gun without bupivacaine pretreatment or intramuscular needle injection with bupivacaine pretreatment. These data indicate that the intramuscular gene gun therapy combined with bupivacaine can lead to a tumorspecific CTL response, and suggest that tumor-specific CTL should contribute to a systemic antitumor effect.
Long-lasting Th1-mediated antitumor immunity in vivo in IL-12 and IL-18 intramuscular gene-gun treatment
To evaluate whether IFN-g levels could be enhanced in vivo after the injection of IL-12 and IL-18 cDNA into the muscle, IFN-g production in the serum of the gene-guntreated rats were compared on days 10 and 28 among the various treatment groups. Higher levels of both IL-12 and IL-18 were also observed in the serum of the combination gene-gun-treatment group (Fig 6a and b) . The IFN-g serum level in the IL-12 plus IL-18 cDNA group was 134 pg/ml on day 10 and 43 pg/ml on day 28 (Fig 6c) , respectively. The IFN-g level was the highest in this group among all the treated groups, although it was not statistically different from the level of transfection with IL-12 cDNA alone. Furthermore, the combination therapy using needle injection with or without bupivacaine also could not maintain significant IFN-g levels as compared with the combination therapy using the gene gun (data not shown). These results suggest that intramuscular gene-gun-treatment of IL-12 and IL-18 Effects of anti-CD4 + , anti-CD8 + , and antiasialo GM1 antibodies on the tumor growth of Yoshida sarcoma
To examine whether CD4 + , CD8 + T cells, or NK cells were involved in the antitumor effect, anti-CD4 + , anti-CD8 + , and antiasialo GM1 antibody were intraperitoneally injected before and after tumor challenge. As shown in Figure 7 , in vivo depletion of ether CD4 + or CD8 + T cells easily permitted progressive tumor growth with the combinatorial gene-gun therapy, compared with control treatment (Po.05). However, there was no difference in tumor growth between the NK-depleted group and the control group. Furthermore, the survival in either the CD4 + or CD8 + T-cell-depleted group was shorter than in the control group (data not shown). These results suggest that CD4 + as well as CD8 + T cells are greatly involved in the antitumor effect of the combinatorial gene-gun therapy, but that NK cells contribute less to the antitumor effect.
Discussion
We have shown in the present study that enhanced expression of the foreign gene in rat skeletal muscle can be sustained for a long time by using the gene gun plus a local anesthetic agent, bupivacaine. Muscle is the most attractive target organ for cytokine gene delivery. Large quantities of skeletal muscle are available and are accessible to the nozzle of the gene gun as well as to needles for injection. The major drawback of muscle injection of expression plasmid is the resulting low levels Figure 6 Long-lasting Th1-predominance in the intramuscular genegun therapy of IL-12 plus IL-18 cDNA. The serum was isolated from sarcoma-bearing rats for IL-12, IL-18, and IFN-g expression analysis. Serum levels of IL-12 (a), IL-18 (b), and IFN-g (c) were evaluated by ELISA. The serum of a tumor-free naive rat was used as a control serum. ND, not done (because all animals died of fatal tumor development at day 11 post-tumor implantation); *, data from only one animal that survived at day 28. Each assay was duplicated, and the average values are indicated. The error bars represent the mean7SD (n ¼ 5). As other anesthetic agents (for example, xylocaine and mepivacaine) are also somewhat able to enhance gene expression, the effect of increased expression of the transgene in muscle may not be limited to bupivacaine. However, bupivacaine causes a highly increased membrane permeability to calcium ions, leading to fiber hypercontraction and inflammation. 47 The inflamed muscle regenerates very rapidly by recruiting satellite cells, which are myogenic stem cells. 48 Myotubes are apparent by 3 days after treatment, and much of the fiber architecture is re-established by 7 days after bupivacaine treatment, as innervation, blood supply, and connective tissues are not significantly disturbed by this treatment. 49 It has been suggested that regenerating muscle fiber may lead to increased transcription of the plasmid DNA. 5, 6 Regarding this point, we also observed an increased number of regenerating multinuclear myotubes that were coupled with DNA synthesis after the bupivacaine treatment (data not shown). Based on this result, it is likely that cell growth, coupled with tissue regeneration, may be essential to the efficient transcription of the foreign gene in vivo.
Plasmid expression is transient after transfection into the cultured fibroblast, and our previous data also indicate that plasmid expression decreases to baseline levels within 3 days of gene-gun transfection into oral mucosa, skin, and liver. 45 Based on the finding that there is no chromosomal integration of plasmid DNA into the myocyte, it has been suggested that persistent expression in muscle may be because of extra chromosomal persistence by the plasmid DNA, but not by the stability of the in vivo transcript or protein. 3 Although the unique mechanism enabling a high potency persistence of the foreign gene in muscle remains to be elucidated, the longterm stability of the transgene in muscle indicates that skeletal muscle is an attractive target tissue for gene therapy.
Since the efficacy of transfection is limited in area and depth, gene-gun therapy appears unsuitable for delivery of therapeutic genes such as antisense, suicide, or tumorsuppressor genes. However, gene-gun technology also has great potential in the field of gene immunization and DNA vaccination against infectious agents and cancer. Although the muscle injection of expression plasmids leads to only low levels of gene expression, a few successful studies of gene expression against mouse tumor models using an intramuscular electroporation delivery of cytokine cDNAs (for example, IFN-g and IL-12) have recently been reported. 50, 51 In those studies, however, only cytokine expression and tumor inhibition have been evaluated. In the present study, we demonstrated the expression efficiency and duration of luciferase and GFP genes in regenerating muscle using the particle-mediated transfer method, although we could not compare the efficacy between intramuscular electroporation and the gene-gun method.
The IL-12 and IL-18 gene therapy combination represents an important advance in immunotherapy, providing an antimetastatic effect against disseminated malignant tumors. This combination also leads to synergistic induction of IFN-g production in serum. Many therapeutic processes in immunology are based on the continuous systemic administration of cytokines, which, unfortunately, is often accompanied by severe complications. 42, 43 In the present study, we were able to achieve a persistent supply of IL-12 and IL-18 from the gene-gun-treated muscle, but did not observe severe toxicity in the days following transfection, suggesting the safety of this therapeutic modality. Therefore, topical intramuscular treatment with IL-12 and IL-18 genes could circumvent some of these complications, and could provide adequate levels of immune-cell activation in response to continuous nonviral gene delivery.
Yoshida sarcoma is a high-grade malignant tumor, and all animals with these tumors that do not undergo treatment will die of tumor dissemination within 2 weeks (around 11 days) after tumor inoculation. Regarding treatment of these tumors, the therapeutic protocol does not involve tumor prevention because we started the gene therapy at 4 days after tumor implantation, by which time the tumors had grown in size and were measurable. However, starting the treatment at more than 5 days posttumor implantation significantly decreases animal survival (our unpublished data), and the timing of the treatment may somehow be affected.
In the present study, the rats whose subcutaneous sarcomas were completely regressed with the combination cytokine therapy rejected the challenge posed by the Yoshida sarcoma. In the group treated with IL-12 and IL-18 cDNAs, tumor-specific CTL was induced, and the IFN-g in serum was also maintained for a long time. In vivo depletion of ether CD4 + or CD8 + T cells resulted in Long-lasting gene expression by gene gun T Ajiki et al the significant suppression of an antitumor effect with combination gene-gun therapy. However, there was little difference in tumor growth between the NK-depleted group and the control group. These results suggest that helper CD4 + T cells as well as cytotoxic CD8 + T cells are greatly involved in the antitumor effect, and may potentially explain why 60% of animals showed complete tumor regression and rejected the tumor rechallenge. IL-12 is a potent and required inducer of efficient IFN-g production by T cells as well as NK cells. 52, 53 Furthermore, IL-12 alone or the combination with IL-18 has also been shown to have potent antiangiogenic activity for tumor growth, even if the tumor is located at a distant site. 40 Therefore, the persistent expression of IL-12 and IL-18 might efficiently recruit antitumor effects to combat the systemic cancerous cells. Combinatorial gene therapy using these antitumor cytokines could thus become one of the most attractive strategies in combating the disseminating aggressive tumors of soft tissue.
